LANCEO
ActiveFrom the official registers: KBO 15 annual accounts at the National Bank publications in the Belgian Official Gazette
Summary
LANCEO has been active since 2011 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €252,857 and a net result of €39,841. Equity has been growing by about 7.9% per year since 2018. Its solvency ranks better than 84% of 75 sector peers (NACE 21, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Overview
Overview
Official details
KBO- Status
- Active since 08-04-2011 Normal situation
- Activity
- Manufacture of basic pharmaceutical products and pharmaceutical preparations NACE 21100and 1 other
- Establishment unit
- 2.199.826.277 2290 Vorselaar, since 08-04-2011
- Financial year end
- 31 December
- Peppol
- Reachable
Financial position
- Bankruptcy probabilitywithin 12 months
- < 0.1%
Annual accounts 2025
- Gross margin
- €63,117
- ▲ 13.4%
- Turnover
- ≈ €190,000
- estimated
- Profit
- €39,841
- ▲ 23.3%
- Equity
- €252,857
- ▲ 18.7%
- Total assets
- €291,955
- ▲ 16.8%
Filed on 30-08-2026, 30 days after the deadlineat the National Bank
Score breakdownlowers riskLiquidity: current ratio 7.39, cash €52,429Founded in 2011Equity €252,857 (86.6% of total assets)Figures for financial year 2025 (filed on 02-09-2026)Show the evidence
Checked score
Score 2025
97
/ 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 79% of micro companies in pharmaceuticals (NACE 21)
Financial strength · tick: 2024
Strong
Solvency
100=
equity 86.6% of total assets
Liquidity
70-4
short-term debt 13.4% · cash 18.0%
Profitability
86+1
return on assets 13.6%
Bankruptcy probability within 12 months
< 0.1%
Very low
0%0.5%1.5%4%10%≥ 25%
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
11-2024: < 0.1%
12-2024: < 0.1%● unchanged vs 11-2024
01-2025: < 0.1%● unchanged vs 12-2024lowest value
02-2025: < 0.1%● unchanged vs 01-2025lowest value
03-2025: < 0.1%● unchanged vs 02-2025lowest value
04-2025: < 0.1%● unchanged vs 03-2025
05-2025: < 0.1%● unchanged vs 04-2025
06-2025: < 0.1%● unchanged vs 05-2025
07-2025: < 0.1%● unchanged vs 06-2025
08-2025: 0.1%▲ +0.1 percentage points vs 07-2025
09-2025: 0.1%● unchanged vs 08-2025highest value
10-2025: < 0.1%▼ -0.1 percentage points vs 09-2025
11-2025: < 0.1%● unchanged vs 10-2025
12-2025: < 0.1%● unchanged vs 11-2025
01-2026: < 0.1%● unchanged vs 12-2025
02-2026: < 0.1%● unchanged vs 01-2026
03-2026: < 0.1%● unchanged vs 02-2026
04-2026: < 0.1%● unchanged vs 03-2026
05-2026: < 0.1%● unchanged vs 04-2026
06-2026: < 0.1%● unchanged vs 05-2026
07-2026: < 0.1%● unchanged vs 06-2026
08-2026: 0.1%▲ +0.1 percentage points vs 07-2026
09-2026: < 0.1%▼ -0.1 percentage points vs 08-2026
10-2026: < 0.1%● unchanged vs 09-2026
Credit of up to €24,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 7.39 (6.46 in 2024), above the usual 1.5. Short-term debt is 13.4% and cash 18% of total assets. 13.4% of the assets are financed with debt and provisions.
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21, micro). It does better than 90% of them on solvency, 72% on liquidity, 79% on profitability and 73% on growth.
The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises risk
raises risk · 2025 accounts filed 30 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 30-08-2026, 30 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filingsDeviation from the deadline
2025
30 days late
2024
29 days late
2023
30 days late
2022
10 days early
2021
29 days late
2020
149 days late
2019
89 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 49 days after the deadline. In the sector (NACE 21), the median for financial year 2024 was 9 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 29 August (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
01-11-2026 today31-12-2026 year end31-07-2027 deadline
Financials
Financials · financial year 2025, micro format
2025 annual accounts filed 30 days after the deadline Filed on 30 August 2026, deadline 31 July 2026 (7 months after the close on 31 December 2025, Companies Code art. 3:10). Source: NBB, 2026-00489055.
Annual accounts 2025 filed on 30-08-2026 at the NBB all 15 filings
Turnover
≈ €190,000
Estimated: probably between €130,000 and €330,000
Total assets
€291,955▲ 16.8%
2024 · €249,869
Net result
€39,841▲ 23.3%
2024 · €32,317
Working capital
€249,972▲ 24.2%
2024 · €201,332
Trend over the years
2021 to 2025, 5 financial years 2018 to 2025, 8 financial years
The operating result for 2025 is 19% higher than in 2024. It is the second rise in a row, after the fall in 2023.
Operating result€53,955
2025
Net result€39,841
2025
Total assets€291,955
2025
Equity€252,857
2025
Debt€39,098
2025
Working capital€249,972
2025
Return on assets (ROA)13.6%
2025
Solvency86.6%
2025
Current ratio7.39
2025
Turnover is what the company sold, the result is what was left of it. A loss stands below the zero line.
Assets, equity and debt per financial year.
Above zero, the company can pay its short-term debts with what it holds in the short term.
The EBIT margin is the share of each euro of turnover left from operations. The return on assets is what the assets earn.
The higher the solvency, the better the company absorbs a setback.
A ratio above 1 means the short-term assets cover the short-term debts.
Use the arrow keys on the chart for the figures per year.
The sector band is the middle half of the companies in Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21). A quarter of them sit below it, a quarter above. Each year counts only accounts in the same format, and only where there are at least 30. The dashed line is the median. There is a sector band for net result, equity, total assets, working capital, solvency, current ratio and return on assets (ROA).
Every figure with its change against the financial year before
favourable
unfavourable
Line20182019202020212022202320242025
Operating result€32,216-€15,817▼ 50.9%€40,912▲ 159%€54,467▲ 33.1%€29,262▼ 46.3%€24,372▼ 16.7%€45,313▲ 85.9%€53,955▲ 19.1%
Net result€23,063-€10,995▼ 52.3%€28,385within the sector's middle half▲ 158%€28,501within the sector's middle half▲ 0.4%€21,342within the sector's middle half▼ 25.1%€16,682within the sector's middle half▼ 21.8%€32,317within the sector's middle half▲ 93.7%€39,841within the sector's middle half▲ 23.3%
Equity€139,118-€150,114▲ 7.9%€178,499within the sector's middle half▲ 18.9%€174,496within the sector's middle half▼ 2.2%€195,838within the sector's middle half▲ 12.2%€203,761above the sector's middle half▲ 4.0%€213,016above the sector's middle half▲ 4.5%€252,857above the sector's middle half▲ 18.7%
Total assets€163,168-€176,514▲ 8.2%€215,945within the sector's middle half▲ 22.3%€264,744within the sector's middle half▲ 22.6%€231,050within the sector's middle half▼ 12.7%€228,900within the sector's middle half▼ 0.9%€249,869within the sector's middle half▲ 9.2%€291,955within the sector's middle half▲ 16.8%
Debt€24,050-€26,401▲ 9.8%€37,446▲ 41.8%€90,248▲ 141%€35,212▼ 61.0%€25,139▼ 28.6%€36,853▲ 46.6%€39,098▲ 6.1%
Working capital€118,675-€132,546▲ 11.7%€165,913above the sector's middle half▲ 25.2%€162,790within the sector's middle half▼ 1.9%€163,416above the sector's middle half▲ 0.4%€182,488above the sector's middle half▲ 11.7%€201,332above the sector's middle half▲ 10.3%€249,972above the sector's middle half▲ 24.2%
Solvency85.3%-85.0%▼ 0.2pp82.7%above the sector's middle half▼ 2.4pp65.9%above the sector's middle half▼ 16.7pp84.8%above the sector's middle half▲ 18.8pp89.0%above the sector's middle half▲ 4.3pp85.3%above the sector's middle half▼ 3.8pp86.6%above the sector's middle half▲ 1.4pp
Current ratio5.93-6.02▲ 0.095.43above the sector's middle half▼ 0.592.80within the sector's middle half▼ 2.635.64above the sector's middle half▲ 2.848.26above the sector's middle half▲ 2.626.46above the sector's middle half▼ 1.807.39above the sector's middle half▲ 0.93
Return on assets (ROA)14.1%-6.2%▼ 7.9pp13.1%within the sector's middle half▲ 6.9pp10.8%within the sector's middle half▼ 2.4pp9.2%within the sector's middle half▼ 1.5pp7.3%within the sector's middle half▼ 1.9pp12.9%within the sector's middle half▲ 5.6pp13.6%within the sector's middle half▲ 0.7pp
above
within
below
The sector band is the middle half of the companies in Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21). A quarter of them sit below it, a quarter above. Each year counts only accounts in the same format, and only where there are at least 30.
Turnover and EBIT margin are not published. The abbreviated or micro format does not require them. The turnover shown is an estimate from the gross margin.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €291,955
Fixed assets
€2,886 ▼ 75.3%
Current assets
€289,069 ▲ 21.4%
Equity and liabilities €291,955
Equity
€252,857 ▲ 18.7%
Debt
€39,098 ▲ 6.1%
Debt's share of the balance-sheet total falls from 14.7% to 13.4%. Equity and debt are higher.
Key figures and ratios
EBITDA
€62,753▲
2024 · €54,903
Cash flow
€48,640▲
2024 · €41,907
Debt to equity
0.15▼
2024 · 0.17
ROE
15.8%▲
2024 · 15.2%
Interest coverage
over 100
2024 · over 100
Debt ≤ 1 year
€39,098▲
2024 · €36,853
Income taxes
€16,112▲
2024 · €13,387
Green means a favourable move, even when the figure itself falls, as with debt or debt to equity.
Comparable companies
These companies have the same main activity as LANCEO: manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21100). They are comparable in size and age: total assets between €158,000 and €582,000, founded between 2005 and 2014.
| Company | Founded | Total assets | Equity | Gross margin | Net result | FTE | Financial year |
|---|---|---|---|---|---|---|---|
| LANCEO Vorselaar | 2011 | €291,955 | €252,857 | €63,117 | €39,841 | - | 2025 |
| CLARETHIS Soignies | 2008 | €172,781 | €85,683 | €61,781 | -€27,994 | - | 2025 |
| YARO PRECLINICAL CONSULTING Turnhout | 2008 | €158,481 | €157,418 | €18,022 | €7,591 | - | 2025 |
| Asclepia MedChem Solutions Destelbergen | 2009 | €360,741 | €284,957 | €206,845 | €130,178 | - | 2025 |
| Joos Clinical Projects Destelbergen | 2009 | €549,074 | €519,440 | €125,355 | €72,838 | - | 2025 |
| PHARMACIE DES PAGODES Genappe | 2005 | €383,064 | €11,549 | €152,066 | €2,425 | 1.6 | 2025 |
| D2S Pharma Oudenaarde | 2014 | €582,318 | €424,697 | €129,195 | €38,474 | 0.5 | 2025 |
They were chosen from the 112 other active companies with that main activity and annual accounts from the past two years. All companies with this main activity
Companies with the same profile, two years later
Historical observationIn July 2024, 34,693 companies had the same profile as LANCEO has now. Two years later, 0.7% had gone bankrupt and 95.3% were still going.
- Micro
- 10 to 20 years old
- solvency 30% or more
- a profit of 5% of the balance sheet or more
0.7%
went bankrupt
3.9%
stopped otherwise
95.3%
was still going
That fits the bankruptcy probability of LANCEO itself: < 0.1% within 12 months.
Test of the method
The method was tested on the 497,445 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 34,693 companies, not a prediction for LANCEO. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Annual accounts
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €4,412 | €4,982 | €4,982 | €5,329 | €9,277 | €11,149 | €9,589 | €8,798 | ▼ 8.3% |
| Other operating charges640/8 | - | - | - | €651 | €657 | €720 | €741 | €364 | ▼ 50.9% |
| Non-recurring operating charges66A | - | - | - | - | €62 | - | - | - | - |
| Gross operating margin9900 | €37,253 | €21,430 | €46,542 | €60,447 | €39,258 | €36,242 | €55,644 | €63,117 | ▲ 13.4% |
| Operating profit (loss)9901 | €32,216 | €15,817 | €40,912 | €54,467 | €29,262 | €24,372 | €45,313 | €53,955 | ▲ 19.1% |
| Financial income75/76B | - | - | - | - | €800 | €329 | €918 | €2,224 | ▲ 142% |
| Recurring financial income75 | - | - | - | - | €800 | €329 | €918 | €2,224 | ▲ 142% |
| Non-recurring financial income76B | - | - | - | - | €800 | - | - | - | - |
| Financial charges65/66B | - | - | - | €562 | €243 | €699 | €527 | €225 | ▼ 57.3% |
| Recurring financial charges65 | €160 | €211 | €283 | €450 | €243 | €699 | €424 | €225 | ▼ 46.9% |
| Non-recurring financial charges66B | - | - | - | €112 | - | - | €103 | - | - |
| Profit (loss) for the period before taxes9903 | €31,864 | €16,209 | €40,423 | €53,905 | €29,819 | €24,003 | €45,704 | €55,954 | ▲ 22.4% |
| Income taxes67/77 | €8,802 | €5,213 | €12,038 | €25,404 | €8,478 | €7,321 | €13,387 | €16,112 | ▲ 20.4% |
| Profit (loss) for the period9904 | €23,063 | €10,995 | €28,385 | €28,501 | €21,342 | €16,682 | €32,317 | €39,841 | ▲ 23.3% |
| Transfer from tax-exempt reserves789 | - | - | - | €42,375 | - | - | - | - | - |
| Profit (loss) for the period to be appropriated9905 | €23,063 | €10,995 | €28,385 | €70,876 | €21,342 | €16,682 | €32,317 | €39,841 | ▲ 23.3% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total assets20/58 | €163,168 | €176,514 | €215,945 | €264,744 | €231,050 | €228,900 | €249,869 | €291,955 | ▲ 16.8% |
| Fixed assets21/28 | €20,443 | €17,568 | €12,585 | €11,707 | €32,422 | €21,273 | €11,684 | €2,886 | ▼ 75.3% |
| Tangible fixed assets22/27 | €20,443 | €17,568 | €12,585 | €11,707 | €32,422 | €21,273 | €11,684 | €2,886 | ▼ 75.3% |
| Plant, machinery and equipment23 | - | - | - | €4,104 | €3,214 | €2,324 | €1,434 | €544 | ▼ 62.1% |
| Furniture and vehicles24 | - | - | - | - | €24,837 | €17,338 | €9,840 | €2,342 | ▼ 76.2% |
| Other tangible fixed assets26 | - | - | - | €7,603 | €4,372 | €1,611 | €410 | - | - |
| Current assets29/58 | €142,725 | €158,947 | €203,359 | €253,038 | €198,628 | €207,627 | €238,185 | €289,069 | ▲ 21.4% |
| Amounts receivable within one year40/41 | €42,822 | €37,007 | €42,756 | €44,668 | €14,857 | €19,417 | €21,055 | €62,490 | ▲ 197% |
| Trade receivables40 | - | - | - | €44,668 | €13,335 | €16,639 | €18,106 | €62,319 | ▲ 244% |
| Other amounts receivable41 | - | - | - | - | €1,522 | €2,778 | €2,949 | €171 | ▼ 94.2% |
| Current investments50/53 | €84,714 | €106,714 | €126,714 | €126,714 | €95,836 | €96,066 | €161,709 | €163,266 | ▲ 1.0% |
| Cash at bank and in hand54/58 | €14,215 | €13,835 | €31,490 | €80,556 | €87,546 | €91,474 | €54,660 | €52,429 | ▼ 4.1% |
| Deferred charges and accrued income490/1 | - | - | - | €1,100 | €389 | €670 | €760 | €10,884 | ▲ 14× |
| Equity and liabilities | |||||||||
| Total equity and liabilities10/49 | €163,168 | €176,514 | €215,945 | €264,744 | €231,050 | €228,900 | €249,869 | €291,955 | ▲ 16.8% |
| Equity10/15 | €139,118 | €150,114 | €178,499 | €174,496 | €195,838 | €203,761 | €213,016 | €252,857 | ▲ 18.7% |
| Contributions10/11 | €6,200 | €6,200 | €6,200 | €6,200 | €6,200 | €6,200 | €6,200 | €6,200 | = |
| Reserves13 | €132,918 | €143,914 | €172,299 | €168,296 | €189,638 | €197,561 | €206,816 | €246,657 | ▲ 19.3% |
| Non-distributable reserves130/1 | - | - | - | €1,860 | €1,860 | - | - | - | - |
| Reserves not available under the articles1311 | - | - | - | €1,860 | €1,860 | - | - | - | - |
| Distributable reserves133 | - | - | - | €166,436 | €187,778 | €197,561 | €206,816 | €246,657 | ▲ 19.3% |
| Amounts payable17/49 | €24,050 | €26,401 | €37,446 | €90,248 | €35,212 | €25,139 | €36,853 | €39,098 | ▲ 6.1% |
| Amounts payable within one year42/48 | €24,050 | €26,401 | €37,446 | €90,248 | €35,212 | €25,139 | €36,853 | €39,098 | ▲ 6.1% |
| Trade debts44 | €3,037 | €4,028 | €796 | €4,260 | €4,673 | €1,948 | €5,008 | €4,379 | ▼ 12.6% |
| Suppliers440/4 | - | - | - | €4,260 | €4,673 | €1,948 | €5,008 | €4,379 | ▼ 12.6% |
| Taxes, remuneration and social security45 | - | - | - | €48,615 | €28,874 | €20,917 | €27,744 | €31,793 | ▲ 14.6% |
| Taxes450/3 | - | - | - | €48,615 | €28,874 | €20,917 | €27,744 | €31,793 | ▲ 14.6% |
| Other amounts payable47/48 | - | - | - | €37,373 | €1,666 | €2,275 | €4,101 | €2,925 | ▼ 28.7% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €23,063 | €10,995 | €28,385 | €28,501 | €21,342 | €16,682 | €32,317 | €39,841 | ▲ 23.3% |
| + Depreciation and write-downs630 | €4,412 | €4,982 | €4,982 | €5,329 | €9,277 | €11,149 | €9,589 | €8,798 | ▼ 8.3% |
| Operating cash flow (approximation) | €27,474 | €15,978 | €33,367 | €33,830 | €30,619 | €27,831 | €41,907 | €48,640 | ▲ 16.1% |
| Investment in fixed assets (approximation) | - | -€2,107 | €0 | -€4,450 | -€29,993 | €0 | €0 | €0 | - |
| Change in cash | - | -€380 | €17,655 | €49,066 | €6,990 | €3,928 | -€36,814 | -€2,231 | ▲ 93.9% |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Latest 10 of 15 filings with the National Bank
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | micro format | 30-08-2026 | 2026-00489055 | NBB |
| 31-12-2024 | micro format | 29-08-2025 | 2025-00473930 | |
| 31-12-2023 | micro format | 30-08-2024 | 2024-00430725 | |
| 31-12-2022 | micro format | 21-07-2023 | 2023-00260488 | |
| 31-12-2021 | micro format | 29-08-2022 | 2022-20354717 | |
| 31-12-2020 | micro format | 27-12-2021 | 2021-81900343 | |
| 31-12-2019 | abbreviated format | 28-10-2020 | 2020-64600009 | |
| 31-12-2018 | abbreviated format | 30-08-2019 | 2019-57500218 | |
| 31-12-2017 | abbreviated format | 31-08-2018 | 2018-57100055 | |
| 31-12-2016 | abbreviated format | 31-08-2017 | 2017-56900393 |
Board & ownership
Directors
Directors
2 directors, last change in 2023
Gunther Coenen
Current
Director (not named in the articles) · in office according to the act of 28-12-2023 · listed in the 2025 annual accounts, filed on 30-08-2026
Ursula Reijnen
Current
Director (not named in the articles) · in office according to the act of 28-12-2023 · listed in the 2025 annual accounts, filed on 30-08-2026
Owners and capital
Capital transactions
Capital over time
- 28-12-2023 Converted to unavailable equity
Mandate history
2 people, 2 in office
- Board
- began earlier
| Name | Functions and periods |
|---|---|
| Gunther Coenen |
|
| Ursula Reijnen |
|
Articles of association
Board and representation
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- “Duur van bestaan, 1”“Algemene kosten, algemene vergadering”
Capital, shares and profit
- Share issue ruleThe articles set how and by whom new shares are issued.
- “Ten minste vijftien dagen vanaf openstelling intekening, naar evenredigheid aantal aandelen”
Audit, dissolution and liquidation
- Dissolution ruleThe articles set when and by whom the company can be dissolved.
- “Vereist voor statutenwijziging, algemene vergadering”“Netto-actief dreigt negatief te worden of is geworden ten gevolge geleden verlies, bestuursorgaan stelt vast dat niet langer vaststaat dat…”
- Liquidation ruleIn a liquidation the creditors are paid first. What is left goes to the shareholders.
- “Krachtens deze statuten, één of meerdere vereffenaars aanduiden,bevoegdheden omlijnen,vergoeding bepalen”
Articles of association, deed of 28-12-2023 (in Dutch)
Network & group
LANCEO shares no director with another company.
Connections & network
2 current directorsThe network starts from the directors of LANCEO. Every other company they run is a node.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Timeline
Acts, filings and financial milestones
Deadline for the 2026 accounts:
2026
30-08
financial year 2025 · micro format · 30 days late
2025
31-12
Financial
Highest result from 2018 to 2025net €39,841 ▲23.3%
The net result of €39,841 is the highest of those years.
29-08
financial year 2024 · micro format · 29 days late
2024
30-08
financial year 2023 · micro format · 30 days late
2023
31-12
Financial
Equity above €200,000equity €203,761 ▲4%
With a profit in every financial year since 2018, equity grows to €203,761.
28-12
Gazette deed
Resignations: Gunther Coenen (director) and Ursula Reijnen (director)Reappointments: Gunther Coenen (director) and Ursula Reijnen (director) · Amendment of the articles · Capital conversion15 points ▸
Gazette deed
Resignations: Gunther Coenen (director) and Ursula Reijnen (director)
Reappointments: Gunther Coenen (director) and Ursula Reijnen (director) · Amendment of the articles · Capital conversion15 points ▸
- General meeting, 12-12-2023
- Amendment of the articles, mentioned 2 times in the deed
- Capital conversion, “statutair onbeschikbare eigen vermogensrekening” (deed in Dutch)
- Reserve release, “vormen en meerderheden van statutenwijziging, opheffing” (deed in Dutch)
- Purpose change
- Other provision, “invoering schriftelijke en elektronische algemene vergadering, éénparigheid van stemmen” (deed in Dutch)
- Other provision, “mogelijkheid uitkering interimdividenden, éénparigheid van stemmen” (deed in Dutch)
- Legal-form conversion, “besloten vennootschap” (deed in Dutch)
- Director resignation, Gunther Coenen (director)
- Director discharge, Gunther Coenen
- Director resignation, Ursula Reijnen (director)
- Director discharge, Ursula Reijnen
- The act holds 3 more points.
21-07
financial year 2022 · micro format
2022
31-12
Financial
Liquidity doublescurrent ratio 5.64
The current ratio rises from 2.80 to 5.64. Short-term debt falls from €90,248 to €35,212.
29-08
financial year 2021 · micro format · 29 days late
2021
27-12
financial year 2020 · micro format · 149 days late
2020
28-10
financial year 2019 · abbreviated format · 89 days late
2019
31-12
Financial
Weakest financial yearnet €10,995 ▼52.3%
The net result drops to €10,995, the lowest from 2018 to 2025. It recovers the following year.
Show earlier events
31-12
Financial
Equity above €150,000equity €150,114 ▲7.9%
With a profit in every financial year since 2018, equity grows to €150,114.
30-08
financial year 2018 · abbreviated format · 30 days late
2018
31-08
financial year 2017 · abbreviated format · 31 days late
2017
31-08
financial year 2016 · abbreviated format · 31 days late
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Register details
Identity
KBO recordName
LANCEO in Dutch
Enterprise number
0835.404.283
Legal form
Private limited company
Status
Active, normale toestand
Founded
08-04-2011
Entity type
Legal entity
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
deed of 28-12-2023 (in Dutch)Name clauseThe company operates under this name according to its articles.
LANCEO
deed of 28-12-2023 (in Dutch)Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
“Vlaams Gewest, Artikel 3”
deed of 28-12-2023 (in Dutch)Registered office and establishments
Registered office
Pallaaraard 30, 2290 Vorselaar, Belgium
Establishments
1 establishment unit since 2011
Activities
NACEBEL 202521100
Manufacture of basic pharmaceutical products and pharmaceutical preparations main activity
73200
Market research and public opinion polling main activity
PurposeThe purpose describes the activities the company may carry out under its articles.
deed of 28-12-2023 (in Dutch)
“Dienstverlening binnen de farmaceutische sector,biotechindustrie,voedingsindustrie en andere industrieën,zoals:procesengineering en…”
20 activities
- Dienstverlening binnen de farmaceutische sector,biotechindustrie,voedingsindustrie en andere industrieën,zoals:procesengineering en projectmanagement voor bestaande en nieuwe installaties en processen;het uitvoeren van kwalificatie- en validatieoefeningen;het uitvoeren van audits met betrekking tot GMP-regelgeving en technische en compliance staat systemen en het organiseren en uitvoeren van trainingen
- Alle activiteiten van dienstverlening inzake sales en marketing
- Alle activiteiten met betrekking tot consulting
- Alle activiteiten met betrekking tot klantenwerving en prospectie voor ondernemingen
- Alle activiteiten met betrekking tot het ontwerpen en onderhouden van websites
- Het ontwerpen en produceren van tuinmeubelen
- De klein- en groothandel in tuinmeubelen
- Het ontwerpen en produceren van alle soorten textielproducten
- De klein- en groothandel in alle soorten textielproducten
- De klein- en groothandel in audio-,video- en domotica installaties
- De installatie van audio-,video- en domotica installaties
- Het verschaffen van alle soorten logies voor kortstondig verblijf
- Het uitbaten van alle soorten accommodaties voor kortstondig verblijf
- Het uitbaten van een opleidingscentrum met accommodatie voor kortstondig verblijf
- Het uitbaten van een multifunctionele ruimte voor seminarie,meetings,incentives,events
- Het leveren van dranken en etenswaren in het kader van de uitbating van een accommodatie voor kortstondig verblijf en een opleidingscentrum
- Het verlenen van managementdiensten
- Hetzij voor eigen rekening,hetzij voor rekening van derden of bij deelneming,hetzij op gelijk welke andere wijze,in België of in het buitenland het doen van alle onroerende verrichtingen in de meest uitgebreide zin,inbegrepen de verhandeling,huur en verhuur en beheer van handelszaken,alsook de aankoop,verkoop,ruil,verkaveling,het laten bouwen,aanpassen,veranderen,inrichten,bebossingen en ontbossingen,het huren of verhuren van alle onroerende goederen,pachten en verpachten en vestigen van erfdienstbaarheden,het beheer ervan alsmede het uitvoeren van alle openbare en privatieve werken,alsmede onroerende leasing,alle handelingen die rechtstreeks of onrechtstreeks met dit voorwerp in verband staan en die van aard zijn om de opbrengst van haar onroerende goederen te bevorderen,zoals het onderhoud,de ontwikkeling,de verfraaiing en de verhuring van deze goederen,alsmede borgstelling voor het goede verloop van verbintenissen door derde personen aangegaan die het genot zouden hebben van deze onroerende goederen
- Het kopen en verkopen,beheren enzovoort van alle roerende goederen en waarden,het beleggen en investeren van gelden en waarden
- Het huren en verhuren van alle roerende goederen
Invoicing and payment
VAT number
BE 0835.404.283
Financial year and general meeting
Accounts at the NBBFinancial year end
31-12
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
Third Thursday of June at 20:00
deed of 28-12-2023 (in Dutch)Sites & property
Location
1 establishment unit
LANCEO
since 2011unit number 2.199.826.277
Buildings and parcels at the address
Ground area
6,594 m²
Building footprint
158 m²
Building volume
1,025 m³
Parcel 13044D0228/00E000, Flanders · tallest building 10.3 m.
1 parcel
Flanders
1
(100%)
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 13044D0228/00E000 | Flanders | 6,594 m² | 1 · 158 m² | 10.3 m · 2 |